重药控股(000950) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 reached ¥17,855,668,091.93, representing a 10.67% increase year-over-year[6] - Net profit attributable to shareholders was ¥378,811,421.27, a significant increase of 55.41% compared to the same period last year[6] - The company reported a basic earnings per share of ¥0.22, marking a 57.14% increase year-over-year[6] - The company experienced a 9.33% increase in total operating revenue for the year-to-date period, totaling ¥50,530,650,217.01[12] - Total operating revenue for the current period reached ¥50,530,650,217.01, an increase of 9.4% from ¥46,218,544,640.38 in the previous period[29] - Net profit for the current period was ¥997,525,931.24, compared to ¥886,828,361.67 in the previous period, representing an increase of 12.5%[33] - The net profit attributable to shareholders of the parent company was ¥779,783,934.66, up from ¥681,536,777.92, marking a growth of 14.5%[33] - The company reported a basic earnings per share of ¥0.45, up from ¥0.39 in the previous period[35] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥56,296,485,256.09, reflecting a 13.27% increase from the end of the previous year[6] - The company's total assets increased to ¥56,296,485,256.09 from ¥49,700,081,320.97, reflecting a growth of 13.0%[28] - Total liabilities increased to ¥43,738,227,793.04 from ¥37,933,537,693.05, reflecting a rise of 15.0%[28] - Total equity rose to ¥12,558,257,463.05, compared to ¥11,766,543,627.92, indicating an increase of 6.7%[28] Cash Flow - The net cash flow from operating activities showed a net outflow of ¥3,881,826,418.20, which is an increase of 36.61% in outflow compared to the previous year[15] - The net cash flow from operating activities for the current period is -3,881,826,418.20 CNY, compared to -2,841,522,531.92 CNY in the previous period, indicating a decline of approximately 36.7%[39] - Total cash inflow from operating activities reached 52,102,274,106.81 CNY, up from 46,904,271,277.26 CNY, reflecting an increase of about 9.4%[39] - Cash outflow from operating activities totaled 55,984,100,525.01 CNY, compared to 49,745,793,809.18 CNY in the previous period, representing an increase of approximately 12.5%[39] - The net cash flow from financing activities was ¥2,453,485,512.99, reflecting a slight decrease of 2.87% compared to the previous year[15] - The net cash flow from financing activities is 2,453,485,512.99 CNY, slightly down from 2,526,070,755.47 CNY in the previous period[39] Accounts Receivable and Inventory - The company's accounts receivable increased by 21.53% to ¥31,579,635,890.44, attributed to the expansion of the sales network and stable business growth[11] - Accounts receivable increased to approximately ¥31.58 billion from ¥25.98 billion, reflecting a growth of about 21.5%[24] - Inventory levels rose by 24.49% to ¥7,532,884,202.32, driven by the expansion of national distribution operations[11] - Inventory as of September 30, 2022, was approximately ¥7.53 billion, an increase from ¥6.05 billion, indicating a growth of about 24.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 53,335[16] - The largest shareholder, Chongqing Pharmaceutical Health Industry Co., Ltd., holds 38.14% of shares, totaling 664,900,806 shares[16] Other Financial Metrics - The weighted average return on equity was 3.66%, an increase of 1.06% compared to the previous year[6] - The company has adjusted its accounting estimates for bad debt provisions, which will not affect previously disclosed financial reports[20] - The company reported a significant increase in prepayments, which rose to approximately ¥1.97 billion from ¥1.36 billion, reflecting a growth of about 45.5%[24] - The company’s goodwill increased to approximately ¥1.54 billion from ¥1.46 billion, showing a growth of about 5.5%[24] - Research and development expenses for the current period were ¥1,159,339.66, down from ¥4,152,443.80, a decrease of 72.0%[33] - The company’s other comprehensive income after tax was -¥321,236.49, compared to -¥2,640,134.24 in the previous period, showing an improvement[35] Cash and Cash Equivalents - The company’s cash and cash equivalents as of September 30, 2022, were approximately ¥4.18 billion, down from ¥5.66 billion at the beginning of the year, representing a decrease of about 26.2%[24] - The ending balance of cash and cash equivalents is 1,804,412,676.04 CNY, up from 1,483,558,995.36 CNY in the previous period[41] - The company reported a total cash and cash equivalents net decrease of 1,626,335,584.58 CNY for the current period, compared to a decrease of 1,124,448,856.81 CNY in the previous period[41]